Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Healthcare Conference, to be held in New York City, September 14th -16th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.
Presentation Details:
| H.C. Wainwright 28th Annual Global Investment Conference | |
| Company Presentation: | September 15, 2026 |
| Time: | 1:30 PM ET |
| Location: | New York, NY |
| Webcast Link: | Company Presentation |
The webcast may also be accessed through Spero's website on the Events + Presentations page. A replay of the webcast will be available for approximately 90 days following the conference. To request a meeting or for more details about the conference please reach out to your institutional contact at H.C. Wainwright.
About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotx.com
Media Inquiries:
media@sperotx.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Why This Vanguard ETF Is One of the Best
The Best AI Stocks to Buy Now
United States